Last reviewed · How we verify

SOLRIAMFETOL HYDROCHLORIDE

FDA-approved approved Small molecule ✓ Verified May 2026 Quality 5/100

SOLRIAMFETOL HYDROCHLORIDE is a drug. It is currently FDA-approved (first approved 2019).

Solemidetol hydrochloride, also known as JZP-110, is being studied for its potential to treat excessive sleepiness, Parkinson's disease, narcolepsy, and obstructive sleep apnea. It is a compound that has undergone clinical trials to assess its safety, efficacy, and pharmacokinetics in these conditions.

At a glance

Generic nameSOLRIAMFETOL HYDROCHLORIDE
ModalitySmall molecule
PhaseFDA-approved
First approval2019

Approved indications

No approved indications tracked.

Common side effects

Serious adverse events

Key clinical trials

Patents

PatentExpiryType

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about SOLRIAMFETOL HYDROCHLORIDE

What is SOLRIAMFETOL HYDROCHLORIDE?

SOLRIAMFETOL HYDROCHLORIDE is a Small molecule drug.

When was SOLRIAMFETOL HYDROCHLORIDE approved?

SOLRIAMFETOL HYDROCHLORIDE was first approved on 2019.

What development phase is SOLRIAMFETOL HYDROCHLORIDE in?

SOLRIAMFETOL HYDROCHLORIDE is FDA-approved (marketed).

What are the side effects of SOLRIAMFETOL HYDROCHLORIDE?

Common side effects of SOLRIAMFETOL HYDROCHLORIDE include Headache, Nausea, Decreased appetite, Insomnia, Anxiety, Bruxism. Serious adverse events: Palpitations, Dyspnea, Constipation, Vomiting.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing